Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
Director, Biostatistics - Early Phase role at Revolution Medicines involves providing statistical leadership and support for clinical development strategy and clinical studies through product life cycle.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
Revolution Medicines